SOLUTIONS
Transforming lives through smart healthcare solutions.
New Cures and Methods
Earlier this year a team led by MediChain founder Dr Baker found hints of a radical new way of testing for and predicting Covid-19. Ultimately, an investigation by our Complex Systems Research Division led to a method called Characteristic Leucocyte Differential Count. The method was published earlier this year in the Journal Life Research. The cost per test is 10% of that of current tests and because it uses existing blood test infrastructure with no need for extra staff or reagents, it can increase test rates by a factor of 500% overnight.
It’s been featured on BBC Television South Today (20 October 2020); Across the country on Heart Radio and in the newspapers The initial investigation won the global Coronahack in London (April 2020), beating hundreds of scientists from around the world including “The brightest minds in the fields of medicine and artificial intelligence . . . 500 Health experts; 500 Data scientists using Real time Covid-19 global health data”
The global pandemic continues
MediChain were also finalists in the “COVID-19 edition” of the US National Pediatric Medical Device Competition in Washington, DC supported by the US Food and Drug Administration (FDA)
Using this technique and linked with live access to national data using MediChain’s Athena system, it is possible to predict exactly where the new outbreaks will occur and lockdown to prevent them, reducing the period of lockdown and preventing second and future waves of COVID-19.
The UK government has awarded MediChain Ltd. funding from Innovate UK to develop a device that clips onto a smartphone to allow CLDC to be applied anywhere at any time by just about anyone.
On 7 Sept 2020 government representatives told the MediChain team that they receive tens of thousands of applications and that accepting MediChain UK’s offering made it One of the top companies at a global level.We believe that judges were excited about the impact that we could have on both the national and global economy and public health.
A far reaching technique
As well as being able to form CLDC, the new device developed by MediChain will be able to perform a large number of blood analyses at a low cost anywhere in the world simply by being clipped onto a smartphone. For CLDC it is robust against multiple variants allowing it to detect where other tests fail, as well as allowing it to pick up infection much earlier even than the gold standard RT-PCR test. This is essential in order to stop infections being spread between countries and in populations as pre-symptomatic, potentially infectious, individuals travel having got through RT-PCR testing due to it being too early to be detected. Using CLDC will form a method that prevents this.
The device developed for smartphones by MediChain has a wide range of other applications including; Leukemia detection, Malaria, Sickle Cell Anemia and potential for expansion into Diabetes and liver function.
MediChain and its sister company Hypatia are currently working to develop a pin-prick blood sample test for Covid-19 that anyone can use with a smartphone.
During the presale or main sale you can buy tokens in blocks of value up of $10000 USD from this site.
There are no ‘free’ tokens. In conventional ICOs tokens have crashed in value due to dumping of tokens which were issued to people who have not paid for them, such as in airdrops or to ‘bounty hunters’. With our tokens, every token is valuable and no one has the incentive to sell them cheaply.
In this case, tokens represent actual shares in the company. In the first instance, we intend to list on three major crypto exchanges immediately it is possible to allow exchange of shares. We intend to release or further tokens through these exchanges, a little like an IEO giving us the ability to grow the token value as the company value grows while giving early buyers liquidity. We have a number of substantial commercial deals on paper and so as these bring in revenue our aim is actually to buy back our own tokens through the exchanges, which should yield the token buyers an excellent return. Ultimately this leaves us the option to have further token issues as the company grows, until ultimately we aim to reach an IPO with the shares.
There are no discounted tokens as such. The tokens are security tokens and as such represent part ownership of the company. Early buyers get these against a lower valuation exactly as business angels (think Shark Tank/Dragons Den) and Venture Capital Firms do. We will not be dropping prices regardless of volume.
Every token buyer will need to go through full KYC as part of our AML policy.